tiprankstipranks
MaxCyte Director Executes Stock Options Sale
Company Announcements

MaxCyte Director Executes Stock Options Sale

MaxCyte (MXCT) has released an update.

Don't Miss our Black Friday Offers:

MaxCyte Inc., a leading cell-engineering company, reported that Stanley Erck, a Non-Executive Director, exercised options on 47,689 shares and sold them at prices ranging from $3.625 to $3.880 per share, which represented 7.94% of his holdings. The transactions were conducted in accordance with a pre-arranged trading plan and resulted in Erck holding 0.2% of the company’s issued stock capital plus additional options and restricted stock units.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
TipRanks UK Auto-Generated NewsdeskMaxCyte’s Revenue Grows and Strategic Moves Unveiled
TipRanks UK Auto-Generated NewsdeskMaxCyte Files Quarterly Report, Highlights Financial Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App